Vaccination with Bharat Biotech's indigeneously developed Covid-19 vaccine, Covaxin, has produced neutralising titres (concentration) against all key emerging variants tested, including the B.1.617 and B.1.1.7, first identified in India and the United Kingdom, the vaccine manufacturer informed on Sunday. As per an infographic, a modest reduction in neutralisation by a factor of 1.95 was observed against the B.1.617 variant compared to the vaccine variant (D614G). It, however, added that despite this reduction, neutralizing titre levels with B.1.617 remain above levels expected to be protective. "No difference in neutralization between B.1.1.7 (first found in the UK) and vaccine strain (D614G) was observed," Bharat Biotech added. These findings are from a study conducted in collaboration with the National Institute of Virology - India Council of Medical Research. Currently two vaccines, Serum Institute’s Covishield and Bharat Biotech’s Covaxin, are being administered in India. More than 18 crore doses have been administered till date. Russia developed Sputnik V is also being administered now. (With Inputs from ANI)
Download Organiser Mobile App:
Mobile App: https://play.google.com/store/apps/de...
Visit Us At:
Follow us on:
Background Music Credits: https://www.bensound.com
Dr S. Jaishankar's visit would ensure engagement with the new coalition government in Israel and provide a fresh boost to the bilateral relationship. New Delhi: External Affairs Minister Dr S. Jaishankar arrived in Tel Aviv on Sunday (October 17) for a three-day visit. The visit is considered crucial since the regime change in Israel and aims to solidify the strategic partnership between the two countries. "Shalom Israel. Arrived on my first visit as External Affairs Mi ...